Skip to main content

AQST

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

AQST Price
Price Chart

Forward-looking statistics

Beta
1.24
Risk
72.20%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees123
Market cap$250.4M

Fundamentals

Enterprise value$299.3M
Revenue$54.2M
Revenue per employee
Profit margin-100.02%
Debt to equity-0.64

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.58
Dividend per share
Revenue per share$0.59
Avg trading volume (30 day)$6M
Avg trading volume (10 day)$5M
Put-call ratio

Macro factor sensitivity

Growth+5.1
Credit+23.9
Liquidity-9.8
Inflation-2.2
Commodities+0.9
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio-6.20
Price to sales6.81
P/E Ratio-6.20
Enterprise Value to Revenue5.52
Price to book-5.83

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Investment Research (June 24, 2025)
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.

Zacks Investment Research (May 12, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free